SMWB vs DSGN vs SEMR vs FULC vs BRZE

For growth investors, Braze, Inc.

(BRZE) is the stronger pick with 24. 4% revenue growth year-over-year, versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). Analysts rate Similarweb Ltd. (SMWB) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Semrush Holdings, Inc.

(SEMR) delivered a total return of -38. 9%, compared to -80. 1% for Similarweb Ltd. (SMWB). Over 10 years, the gap is even starker: SEMR returned -14. 3% versus SMWB's -80. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Braze, Inc.

(BRZE) is the lower-risk stock at 0. 98β versus Similarweb Ltd. 's 1. 79β — meaning SMWB is approximately 82% more volatile than BRZE relative to the S&P 500. On balance sheet safety, Design Therapeutics, Inc. (DSGN) carries a lower debt/equity ratio of 0% versus 186% for Similarweb Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Braze, Inc.

(BRZE) is pulling ahead at 24. 4% versus -100. 0% for Fulcrum Therapeutics, Inc. (FULC). On earnings-per-share growth, the picture is similar: Braze, Inc. grew EPS -19. 6% year-over-year, compared to -637. 5% for Fulcrum Therapeutics, Inc.. Over a 3-year CAGR, BRZE leads at 27. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Design Therapeutics, Inc.

(DSGN) is the more profitable company, earning 0. 0% net margin versus -17. 8% for Braze, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DSGN leads at 0. 0% versus -19. 6% for BRZE. At the gross margin level — before operating expenses — SEMR leads at 80. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Similarweb Ltd.

(SMWB) trades at 25. 9x forward P/E versus 36. 5x for Braze, Inc. — 10. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FULC: 513. 4% to $20. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Braze, Inc.

(BRZE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98)). Similarweb Ltd. (SMWB) carries a higher beta of 1. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRZE: -75. 2%, SMWB: -80. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SMWB (Communication Services) and DSGN (Healthcare) and SEMR (Technology) and FULC (Healthcare) and BRZE (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SMWB is a small-cap quality compounder stock; DSGN is a small-cap quality compounder stock; SEMR is a small-cap high-growth stock; FULC is a small-cap quality compounder stock; BRZE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.